Shoji Kubo, Shinji Uemoto, Hiroyuki Furukawa, Koji Umeshita, Daisuke Tachibana, for the Japanese Liver Transplantation Society – 30 January 2014 – A national survey of pregnancy outcomes after living donor liver transplantation (LDLT) was performed in Japan. Thirty‐eight pregnancies in 30 recipients resulted in 31 live births (25 recipients), 3 artificial abortions in the first trimester (3 recipients), 1 spontaneous abortion (1 recipient), and 3 fetal deaths (3 recipients).

Ping Wan, Xin Yu, Qiang Xia – 30 January 2014 – Living donor liver transplantation (LDLT) has emerged as an alternative to deceased donor liver transplantation (DDLT) because of the increasing number of patients waiting for liver transplantation (LT). However, whether it can achieve operative outcomes similar to those achieved with DDLT for adult patients remains controversial. We conducted this meta‐analysis to compare the operative outcomes of LDLT and DDLT recipients.

Mi‐Jung Jun, Ju Hyun Shim, So Yeon Kim, Nieun Seo, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Eunsil Yu, Sung‐Gyu Lee – 30 January 2014 – The role of liver biopsy in selecting optimal donors is an area of continuing controversy in living donor liver transplantation (LDLT). Our aim was to assess the potential implications of preoperative and intraoperative biopsies for evaluating donor liver fat content.

Jean‐François Dufour – 29 January 2014

Jean‐François Dufour – 29 January 2014

Timucin Taner, Mark D. Stegall, Julie K. Heimbach – 27 January 2014 – Interest in the role of donor‐specific human leukocyte antibodies in liver transplantation has been rekindled recently. Emerging evidence suggests that these antibodies may cause injury to the liver allograft. Here we review the clinical literature, highlight controversial results, and propose a path forward for the definition and better understanding of antibody‐mediated injury to the liver. Liver Transpl 20:514–527, 2014. © 2014 AASLD.

Rabindranath Bera, Chih‐Yung Chiou, Ming‐Chin Yu, Jei‐Ming Peng, Chung‐Ru He, Chih‐Yun Hsu, Hsiao‐Ling Huang, Uda Y. Ho, Shi‐Ming Lin, Yu‐Jr Lin, Sen‐Yung Hsieh – 27 January 2014 – It is unclear how proliferating cells elicit suppression on cell proliferation and how cancer cells evade this growth suppression.

Jonathan A. Dranoff, Jordan J. Feld, Élise G. Lavoie, Michel Fausther – 27 January 2014

Pierre‐Emmanuel Rautou, Anne‐Clémence Vion, James P. Luyendyk, Nigel Mackman – 27 January 2014

Hua Zhang, Calvin Q. Pan, Qiumei Pang, Ruihua Tian, Miaoe Yan, Xin Liu – 27 January 2014 – Little observational data exist describing telbivudine (LdT) or lamivudine (LAM) use in late pregnancy for preventing hepatitis B mother‐to‐child transmission (MTCT) in real‐world settings. During the period of January 2009 to March 2011, we enrolled hepatitis B e antigen–positive mothers with HBV DNA >6 log10 copies/mL in China. At gestation week 28, the mothers received LdT or LAM until postpartum week 4 or no treatment (NTx). The study endpoints were the safety of LdT/LAM use and MTCT rates.